Deciphera Pharmaceuticals Inc (DCPH)


Stock Price Forecast

Feb. 16, 2024


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Deciphera Pharmaceuticals Inc chart...

About the Company

Deciphera is a biopharmaceutical company focused on discovering, developing and commercializing important new medicines to improve the lives of people with cancer. The Company is leveraging its proprietary switch-control kinase inhibitor platform and deep expertise in kinase biology to develop a broad portfolio of innovative medicines. In addition to advancing multiple product candidates from its platform in clinical studies, QINLOCK is Deciphera's FDA-approved switch-control kinase inhibitor for the treatment of fourth-line gastrointestinal stromal tumor (GIST). QINLOCK is also approved for fourth-line GIST in Canada and Australia.

Employees

350

CEO

Steven Hoerter

Exchange

NASDAQ

Website

www.deciphera.com

$100M

Total Revenue

350

Employees

$803M

Market Capitalization

-2.82

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $DCPH News

Why Is Deciphera Pharmaceuticals, Inc. (DCPH) Up 20.8% Since Last Earnings Report?

11d ago, source:

Deciphera Pharmaceuticals, Inc. (DCPH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Why Is Biogen Inc. (BIIB) Up 2.6% Since Last Earnings Report?

4d ago, source: Zacks.com on MSN

Biogen Inc. belongs to the Zacks Medical - Biomedical and Genetics industry. Another stock from the same industry, Deciphera Pharmaceuticals, Inc. (DCPH), has gained 4.6% over the past month. More ...

Analysts Conflicted on These Healthcare Names: Cadrenal Therapeutics, Inc. (CVKD), Protara Therapeutics (TARA) and Spruce Biosciences (SPRB)

4d ago, source: Business Insider

Fein covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Amylyx Pharmaceuticals Inc, and Deciphera Pharmaceuticals. Currently, the analyst consensus on Protara ...

Analysts Offer Insights on Healthcare Companies: Black Diamond Therapeutics (BDTX) and I-MAB (IMAB)

23h ago, source: Business Insider

Fein covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Amylyx Pharmaceuticals Inc, and Deciphera Pharmaceuticals. I-MAB has an analyst consensus of Strong Buy, ...

11 Best Small Cap Pharma Stocks to Invest In

14d ago, source: InvestingChannel on MSN

For pharma stocks, these can be either big ticket and stable names such as Pfizer Inc. (NYSE:PFE) and Johnson & Johnson (NYSE ...

Madrigal Pharma: Rezdiffra Gets First FDA Approval For NASH

4d ago, source:

(RTTNews) - Madrigal Pharmaceuticals, Inc. (MDGL) announced that the U.S. Food and Drug Administration (FDA) has approved Rezdiffra (resmetirom) along with diet and exercise for the treatment of ...

Mirum gains as FDA accepts label expansion of liver disease drug

on MSN ago, source:

Mirum Pharmaceuticals' Livmarli receives FDA approval for the treatment of cholestatic pruritus in patients with progressive ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...